The Japan Times - US panel weighs authorizing Covid vaccines for youngest children

EUR -
AED 4.246429
AFN 76.887634
ALL 93.189144
AMD 423.342651
AOA 1060.176801
ARS 1724.882575
AUD 1.635501
AWG 2.082489
AZN 1.97002
BAM 1.961391
BBD 2.328337
BDT 143.102254
BHD 0.435984
BIF 3453.955207
BMD 1.156136
BND 1.481323
BOB 13.739522
BRL 5.876989
BSD 1.155995
BTN 110.001186
BWP 15.603479
BYN 3.442212
BYR 22660.258427
BZD 2.324897
CAD 1.613446
CDF 2615.761404
CHF 0.934181
CLF 0.026749
CLP 1056.199727
CNY 7.801146
CNH 7.796152
COP 3650.105178
CRC 525.509359
CUC 1.156136
CUP 30.637594
CVE 110.646682
CZK 24.258158
DJF 205.46888
DKK 7.477932
DOP 67.345355
DZD 153.688625
EGP 57.293288
ERN 17.342035
ETB 184.982115
FJD 2.553384
FKP 0.859288
GBP 0.856968
GEL 3.017966
GGP 0.859288
GHS 13.596606
GIP 0.859288
GMD 84.980421
GNF 10145.090599
GTQ 8.820142
GYD 241.849406
HKD 9.067746
HNL 31.077375
HRK 7.536622
HTG 151.150865
HUF 363.096405
IDR 20580.370421
ILS 3.468234
IMP 0.859288
INR 109.992259
IQD 1515.115748
IRR 1590322.371805
ISK 142.598215
JEP 0.859288
JMD 183.583315
JOD 0.819746
JPY 182.445186
KES 148.887592
KGS 101.104505
KHR 4685.244046
KMF 492.514185
KRW 1627.712241
KWD 0.356853
KYD 0.963346
KZT 541.784389
LAK 26108.437325
LBP 103531.946431
LKR 387.745291
LRD 209.896866
LSL 18.648909
LTL 3.413768
LVL 0.699335
LYD 7.358849
MAD 10.757887
MDL 20.102303
MGA 4982.944983
MKD 61.70777
MMK 2427.367709
MNT 4157.510076
MOP 9.34149
MRU 46.349915
MUR 54.396619
MVR 17.862733
MWK 2008.207995
MXN 19.811776
MYR 4.728715
MZN 73.882892
NAD 18.78764
NGN 1577.963717
NIO 42.540713
NOK 10.99759
NPR 176.001898
NZD 1.961547
OMR 0.442559
PAB 1.15598
PEN 3.913564
PGK 5.112721
PHP 70.183258
PKR 321.178758
PLN 4.299905
PYG 6873.802279
QAR 4.213541
RON 5.244583
RSD 117.953626
RUB 94.679224
RWF 1693.738704
SAR 4.370455
SBD 9.325039
SCR 16.735107
SDG 694.263698
SEK 10.961095
SGD 1.477777
SLE 28.445176
SOS 694.263682
SRD 43.778814
STD 23929.673396
STN 24.712399
SVC 10.11514
SZL 18.781467
THB 38.210709
TJS 10.664099
TMT 4.058036
TND 3.366711
TRY 55.144784
TTD 7.835505
TWD 37.286072
TZS 3060.872603
UAH 51.775757
UGX 4306.406038
USD 1.156136
UYU 46.534057
UZS 13815.821213
VES 873.763846
VND 30295.956222
VUV 137.592149
WST 3.154418
XAF 657.83219
XAG 0.018216
XAU 0.000266
XCD 3.124515
XCG 2.083439
XDR 0.818768
XOF 656.685424
XPF 119.331742
YER 275.626884
ZAR 18.667336
ZMK 10406.612213
ZMW 21.818913
ZWL 372.275202
  • CMSC

    0.0240

    21.744

    +0.11%

  • CMSD

    -0.1600

    21.82

    -0.73%

  • BP

    -0.6000

    41.63

    -1.44%

  • RBGPF

    0.6500

    70.6

    +0.92%

  • BCE

    -0.0200

    22.75

    -0.09%

  • RIO

    1.4500

    101.1

    +1.43%

  • GSK

    0.7900

    52.96

    +1.49%

  • NGG

    0.4700

    80.88

    +0.58%

  • BTI

    0.6000

    59.33

    +1.01%

  • RYCEF

    0.0500

    21

    +0.24%

  • VOD

    0.1900

    16.19

    +1.17%

  • RELX

    0.0485

    35.52

    +0.14%

  • BCC

    2.3400

    86.6

    +2.7%

  • JRI

    0.1500

    12.81

    +1.17%

  • AZN

    1.4100

    161.42

    +0.87%

US panel weighs authorizing Covid vaccines for youngest children
US panel weighs authorizing Covid vaccines for youngest children / Photo: Frederic J. BROWN - AFP/File

US panel weighs authorizing Covid vaccines for youngest children

After months of anxious wait for some parents, a panel of experts convened by the US Food and Drug Administration will meet Wednesday to weigh recommending Covid vaccines for the nation's youngest children.

Text size:

Children under five are the only age group not yet eligible for Covid immunization in the United States and most other countries. If, as expected, panelists vote in favor of greenlighting the Pfizer and Moderna vaccines, formal authorizations should follow quickly, with the first shots in arms expected by next week.

Ahead of the meeting, the FDA posted its independent analyses of the two drugs, deeming both safe and effective. It also said there was a pressing unmet need to inoculate children in the age group since their rates of hospitalization and death "are higher than among children and adolescents 5-17 years of age."

Both vaccines are based on messenger RNA technology, which delivers genetic code for the coronavirus spike protein to human cells, training the immune system to be ready for when it encounters the real virus.

Pfizer is seeking authorization for three doses at three micrograms given to ages six months through four years, while Moderna has asked for the FDA to approve its vaccine as two doses of a higher 30 micrograms, for ages six months through five years.

They were tested in trials of thousands of children where they were found to have similar levels of mild effects to older age groups and triggered similar levels of antibodies.

Efficacy against infection was higher for Pfizer, with the company placing it at 80 percent compared to Moderna's estimates of 51 percent in the six-month-old to age two group and 37 percent in the two to five years age group.

But the figures are provisional and Moderna is studying adding a third dose later that may increase its figures.

There are some 20 million US children aged four years and under. If the FDA-appointed experts recommend the two vaccines, then the matter will go to another committee convened by the Centers for Disease Control and Prevention for a final say.

White House officials last week said the rollout of millions of shots at pharmacies and doctors' offices could begin as soon as June 21, following the Juneteenth holiday on June 20.

Of the total US Covid deaths, 480 have come in children under five, according to the latest official data.

Obesity, neurological disorders and asthma are associated with increased risk of severe disease, "however, a majority of children hospitalized for Covid-19 have no underlying medical conditions," the FDA said in a document.

Children can also go on to contract multisystem inflammatory syndrome in children (MIS-C), a rare but serious post-viral condition.

Data on long Covid in children is sparse, but the FDA's document cited a national survey in the United Kingdom which found that "among children ages two to 11 years who tested positive for COVID-19, 7.2 percent reported continued symptoms at 12 weeks."

K.Okada--JT